195832-15-6

Upstream product

• 195832-14-5 S-3-hydroxymethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester 
• 200644-47-9 (S)-3,4-Dihydro-1H-isoquinoline-2,3-dicarboxylic acid 2-benzyl ester 3-methyl ester 
• 501-53-1 benzyl chloroformate 
• 74163-81-8 L-Tic-OH 

Downstream Products

• 762245-21-6 3-(bis-ethylsulfanyl-methyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester 
• 762245-24-9 (2-amino-4-benzyloxy-5-methoxy-phenyl)-[3-(bis-ethylsulfanyl-methyl)-3,4-dihydro-1H-isoquinolin-2-yl]-methanone 
• 762245-23-8 (4-benzyloxy-5-methoxy-2-nitro-phenyl)-[3-(bis-ethylsulfanyl-methyl)-3,4-dihydro-1H-isoquinolin-2-yl]-methanone 
• 762245-25-0 2-benzyloxy-12-hydroxy-3-methoxy-11,11a,12,13-tetrahydro-6H-5a,13-diaza-benzo[4,5]cyclohepta[1,2-b]naphthalen-5-one 

Relevant academic research and scientific papers

Synthesis of a novel tetrahydroisoquinolino[2,1-c][1,4]benzodiazepine ring system with DNA recognition potential

The first stereospecific synthesis of a novel tetrahydroisoquinolino[2,1-c] [1,4]benzodiazepine ring system with DNA recognition potential starting from (S)-1,2,3,4-tetrahydroisoquinoline carboxylic acid has been reported. We report the first stereospecif

Isoquinolines useful as analgesics

PCT No. PCT/SE97/00315 Sec. 371 Date Oct. 6, 1997 Sec. 102(e) Date Oct. 6, 1997 PCT Filed Feb. 25, 1997 PCT Pub. No. WO97/31940 PCT Pub. Date Sep. 4, 1997The present invention is directed to compounds that act as analgesics and that have the structure of